We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
VYNE Therapeutics Inc | NASDAQ:VYNE | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.13 | -5.14% | 2.40 | 2.00 | 3.72 | 2.53 | 2.40 | 2.53 | 29,242 | 01:00:00 |
| | |
Per Share of
Common Stock |
| |
Total
|
| ||||||
Offering price
|
| | | $ | 2.37 | | | | | $ | 49,999,999.02 | | |
Placement agent fees(1)
|
| | | $ | 0.1422 | | | | | $ | 2,999,999.95 | | |
Proceeds to VYNE Therapeutics Inc., before expenses
|
| | | $ | 2.2278 | | | | | $ | 46,999,999.07 | | |
| | |
Page
|
| |||
| | | | S-ii | | | |
| | | | S-1 | | | |
| | | | S-3 | | | |
| | | | S-4 | | | |
| | | | S-7 | | | |
| | | | S-9 | | | |
| | | | S-10 | | | |
| | | | S-11 | | | |
| | | | S-12 | | | |
| | | | S-15 | | | |
| | | | S-17 | | | |
| | | | S-17 | | | |
| | | | S-18 | | | |
| | | | S-18 | | |
| | | | | 1 | | | |
| | | | | 2 | | | |
| | | | | 4 | | | |
| | | | | 5 | | | |
| | | | | 6 | | | |
| | | | | 7 | | | |
| | | | | 8 | | | |
| | | | | 13 | | | |
| | | | | 20 | | | |
| | | | | 21 | | | |
| | | | | 22 | | | |
| | | | | 23 | | | |
| | | | | 27 | | | |
| | | | | 29 | | | |
| | | | | 29 | | |
|
Offering price per share
|
| | | | | | | | | $ | 2.37 | | |
|
Net tangible book value per share before this offering, as of September 30, 2020
|
| | | $ | 0.29 | | | | | | | | |
|
Increase in net tangible book value per share attributable to investors in this offering
|
| | | $ | 0.22 | | | | | | | | |
|
As adjusted net tangible book value per share after offering
|
| | | | | | | | | $ | 0.51 | | |
|
Dilution in as adjusted net tangible book value per share to new investors
|
| | | | | | | | | $ | 1.86 | | |
| | |
Per Share of
Common Stock |
| |||
Placement agent fees
|
| | | $ | 0.1422 | | |
Total
|
| | | $ | 2,999,999.95 | | |
| | | | | 1 | | | |
| | | | | 2 | | | |
| | | | | 4 | | | |
| | | | | 5 | | | |
| | | | | 6 | | | |
| | | | | 7 | | | |
| | | | | 8 | | | |
| | | | | 13 | | | |
| | | | | 20 | | | |
| | | | | 21 | | | |
| | | | | 22 | | | |
| | | | | 23 | | | |
| | | | | 27 | | | |
| | | | | 29 | | | |
| | | | | 29 | | |
| | |
Year Ended December 31,
|
| |
Nine Months
Ended September 30, 2018 |
| ||||||||||||||||||
(in thousands)
|
| |
2017
|
| |
2016
|
| |
2015
|
| |||||||||||||||
Deficiency of earnings available to cover fixed charges
|
| | | $ | 29,076 | | | | | $ | 14,068 | | | | | $ | 4,608 | | | | | $ | 33,852 | | |
1 Year VYNE Therapeutics Chart |
1 Month VYNE Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions